Vistagen Stock Plunges After Social Anxiety Drug Fails Phase 3 Trial

Vistagen Therapeutics stock crashes after fasedienol, its experimental nasal spray for social anxiety disorder, fails to meet primary endpoints in Phase 3 PALISADE-3 trial.